November 2021 – Kinstellar has successfully advised the US-based X-Chem, on the acquisition of a 100% stake in ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
X-Chem, backed by GHO Capital Partners LLP, is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. ComInnex is a synthetic chemistry group passionate about small molecule design and synthesis. Based in Budapest, Hungary, ComInnex supports early-stage drug discovery through a range of products and services, focusing on the latest technologies and adapting to new and emerging trends.
Kinstellar advised on all stages of the transaction, including due diligence, transaction advisory as well as regulatory issues. "We are pleased to have worked with X-Chem throughout the transaction, whose highly professional team made the cooperation very smooth. This was a true win-win transaction, creating a synergy between two Parties which promises to be highly beneficial for both. I am pleased that we were able to contribute to this success story." commented by Partner Anthony O'Connor (Partner, Budapest).
Anthony led the Kinstellar team, working with Ágnes Zsófia Szabó (Managing Associate, Budapest), Eszter Takácsi-Nagy (Senior Associate, Budapest), Bertalan Ványa (Junior Associate, Budapest) and Judit Sós (Junior Associate, Budapest).
"Finding a trusted partner on the ground is critical in cross border transactions. Anthony and the Kinstellar team in Budapest were very professional and provided excellent advice as we navigated a complex transaction." commented Terry Loding, Chief Operating Officer, X-Chem.